Navigation Links
NuVasive To Present at the Piper Jaffray Health Care Conference and the J.P. Morgan SMid Cap Conference
Date:11/23/2009

SAN DIEGO, Nov. 23 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Alex Lukianov, Chairman and Chief Executive Officer, and Michael J. Lambert, Executive Vice President and Chief Financial Officer, are scheduled to present at the 21st Annual Piper Jaffray Health Care Conference at the New York Palace in New York, New York, on Wednesday, December 2, 2009, at 10:00 a.m. ET. Mr. Lukianov and Mr. Lambert are also scheduled to present at the J.P. Morgan SMid Cap Conference at the J.P. Morgan Conference Center at 383 Madison Avenue in New York, New York, on Thursday, December 3, 2009, at 1:30 p.m. ET.

A live webcast of both presentations will be available online from the investor relations page of the Company's corporate website at www.nuvasive.com. After the live webcast, the presentations will remain available on the website for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development, and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused primarily on the $4.6 billion U.S. spine implant market. Additionally, the Company has expanded into the $1.5 billion global biologics market, the $1.5 billion international market, and is developing products for the emerging motion preservation market.

NuVasive's principal product offering is based on its Maximum Access Surgery, or MAS® platform. The MAS platform combines four categories of products that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: NeuroVision®, a proprietary software-driven nerve avoidance system; MaXcess®, a unique split-blade retractor system; a wide variety of specialized implants; and several biologic fusion enhancers. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. Having redefined spine surgery with the MAS platform's lateral approach, known as eXtreme Lateral Interbody Fusion, or XLIF®, NuVasive has built an entire spine franchise. With nearly 50 products today spanning lumbar, thoracic and cervical applications, the Company will continue to expand and evolve its offering predicated on its R&D focus and dedication to outstanding service levels supported by a culture of Absolute Responsiveness®.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.


Contact:                           Investors:
Michael Lambert                    Patrick F. Williams
EVP & Chief Financial Officer      Vice President, Finance &
NuVasive, Inc.                      Investor Relations
858-909-1998                       NuVasive, Inc.
investorrelations@nuvasive.com     858-638-5511
                                   investorrelations@nuvasive.com

Media:
Jason Rando
The Ruth Group
646-536-7025
jrando@theruthgroup.com

SOURCE NuVasive, Inc.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. NuVasive to Present at the JMP Securities Healthcare Focus Conference
2. NuVasive Announces Conference Call and Webcast of Third Quarter 2009 Results
3. NuVasive to Present at the Oppenheimer 20th Annual Healthcare Conference
4. NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... -- France , Germany , ... Israel ). It includes a 10-year epidemiology forecast for ... by age and sex in these markets. GD epidemiology report is written ... high quality, transparent and market-driven, providing expert analysis of disease trends in ... , Italy , Spain , ...
(Date:2/4/2016)... 4, 2016  The Senior Care Pharmacy Coalition ... Committee Chairman Jason Chaffetz (R-UT) and ... hearing , "Developments in the Prescription Drug ... growing questions about abusive pharmacy benefit manager (PBM) ... and Ranking Member Elijah Cummings (D-MD) are diligent, ...
(Date:2/4/2016)... Wegener Polyangiitis - Pipeline Review, H2 ... Polyangiitis - Pipeline Review, H2 2015, provides an ... This report provides comprehensive information on the therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ...
Breaking Medicine Technology:
(Date:2/5/2016)... Francisco, CA (PRWEB) , ... February 05, 2016 ... ... and founder of CitiDent, announces that it is now welcoming orthodontist, ... Dr. Cheng, CitiDent offers a complete range of oral health care, including general ...
(Date:2/5/2016)... ... February 05, 2016 , ... Health and wellness is a ... individuals in the event they are experiencing an illness. Migraines are a severe form ... are afflicted with migraines would not wish the pain on their worst enemy, the ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Calls Blacklist ... a completely new user interface design and the developer has fixed known bugs within ... they want to on their phone while not consuming any of their device’s battery ...
(Date:2/5/2016)... CA (PRWEB) , ... February 05, 2016 , ... ... that Medicare San Luis Obispo users can expect to see in 2016. To view ... two most significant changes will directly impact many San Luis Obispo seniors who rely ...
(Date:2/4/2016)... ... February 04, 2016 , ... According to a recent ... see their dentist once every six months for a cleaning and checkup, depending on ... Dr. Farzad Feiz, head dentist at Calabasas Dental Group and California Dental Care, notes ...
Breaking Medicine News(10 mins):